

## Curriculum of Research

### Personal Data

Name Laudes, Matthias Prof. Dr. med.  
Place/Date of Birth Idar-Oberstein, Germany / 22.07.1972

### Affiliation

Institution Kiel University (CAU) / UKSH, Campus Kiel  
Institute/Department Medical Department I, Internal Medicine  
Address Arnold-Heller-Str. 3  
City, Zip Code Kiel, 24105  
Phone +49 431 500 22217  
Fax +49 431 500 22204  
e-mail matthias.laudes@uksh.de

### Education/Training

1992 - 1998 Study of Medicine and MD thesis, Johannes Gutenberg University Mainz  
1999 - 2001 Resident in Internal Medicine, University of Cologne  
2001 - 2003 Postdoctoral Fellow (DFG funded), Dept. of Clinical Biochemistry, University of Cambridge (UK)  
2004 - 2011 Resident in Internal Medicine, University of Cologne  
since 2007 Board certification as a specialist in Internal Medicine, in Endocrinology and Diabetology  
since 2009 Board certification as a specialist in Rheumatology

### Research Experience/Academic Appointments

since 2018 Professor and Chair of Endocrinology, Diabetes and Clinical Nutrition  
since 2018 Head of Division of Endocrinology, Diabetes and Clinical Nutrition, Department of Internal Medicine I, Kiel University  
2011- 2018 Professor of Clinical Nutritional Medicine, Kiel University  
2011- 2018 Head of Division of Clinical Nutrition and Metabolic Medicine, Department of Internal Medicine I, Kiel University

### Important Scientific Prizes/Functions

2001 DFG Research Grant  
since 2017 Schleswig-Holstein Excellence Chair  
2017 Ferdinand Bertram Prize (20,000 EUR), DDG  
2018 Prevention Prize (10,000 EUR), DGIM

### Current Projects

2019 – ongoing EXC, 2167, Research and Technology Field V, Clinical Demonstrator 2  
2017 - 2020 ERA, BioNUGUT - gut metabolites as biomarkers for nutrition and health  
2017 - 2018 EXC 306, Targeted microbiome intervention for remission of prediabetes  
2015 - 2018 RTG 1743, Role of fatty acids in wnt signaling in metabolic inflammation  
2015 - 2017 EXC 306, Targeted microbiome intervention by slow-release niacin  
2015 - 2017 EXC 306, GPR120 receptor signaling in metabolic inflammation  
2014 - 2019 BMBF, SysInflame - redefinition of clinical phenotypes in chronic inflammation diseases

### Ten Main Publications

- Hollstein T, Schulte DM, Schulz J, Glück A, Ziegler AG, Bonifacio E, Wendorff M, Franke A, Schreiber S, Bornstein SR, Laudes M. (2020) Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection: a case report, **Nat Metab.** doi: 10.1038/s42255-020-00281-8
- Reitmeier S, Kiessling S, Clavel T, List M, Almeida EL, Ghosh TS, Neuhaus K, Grallert H, Linseisen J, Skurk T, Brandl B, Breuninger TA, Troll M, Rathmann W, Linkohr B, Hauner H, Laudes M. Franke A, Le Roy CI, Bell JT, Spector T, Baumbach J, O'Toole PW, Peters A, Haller D. (2020) Arrhythmic Gut Microbiome Signatures Predict Risk of Type 2 Diabetes. **Cell Host Microbe.** 28(2):258-272.e
- Fangmann D, Geisler C, Schlicht K, Hartmann K, Köpke J, Tiede A, Settgast U, Türk K, Schulte DM, Altmann K, Clawin-Rädecker I, Lorenzen PC, Schreiber S, Schwarz K, Laudes M. (2020) Differential effects of protein intake versus intake of a defined oligopeptide on FGF-21 in obese human subjects in vivo. **Clin Nutr.** S0261-5614(20)30296-X.
- Pryor R, Norvaisas P, Marinos G, Best L, Thingholm LB, Quintaneiro LM, De Haes W, Esser D, Waschina S, Lujan C, Smith RL, Scott TA, Martinez-Martinez D, Woodward O, Bryson K, Laudes

- M. Lieb W, Houtkooper RH, Franke A, Temmerman L, Bjedov I, Cochemé HM, Kaleta C, Cabreiro F. (2019) Host-Microbe-Drug-Nutrient Screen Identifies Bacterial Effectors of Metformin Therapy. **Cell**. 178(6):1299-1312.e29.
5. Fangmann D, Theismann EM, Türk K, Schulte DM, Relling I, Hartmann K, Keppler JK, Knipp JR, Rehman A, Heinsen FA, Franke A, Lenk L, Freitag-Wolf S, Appel E, Gorb S, Brenner C, Seegert D, Waetzig GH, Rosenstiel P, Schreiber S, Schwarz K, Laudes M (2018). Targeted microbiome intervention by microencapsulated delayed-release niacin beneficially affects insulin sensitivity in humans. **Diabetes Care**. 41:398-405
  6. Thingholm LB, Rühlemann MC, Koch M, Fuqua B, Laucke G, Boehm R, Bang C, Franzosa EA, Hübenthal M, Rahnavard A, Frost F, Lloyd-Price J, Schirmer M, Lusic AJ, Vulpe CD, Lerch MM, Homuth G, Kacprowski T, Schmidt CO, Nöthlings U, Karlsen TH, Lieb W, Laudes M, Franke A, Huttenhower C. (2019) Obese Individuals with and without Type 2 Diabetes Show Different Gut Microbial Functional Capacity and Composition. **Cell Host Microbe**. 26(2):252-264.e10.
  7. Relling I., Akcay G., Fangmann, D., Knappe, C., Schulte, D.M., Hartmann, K., Müller, N., Türk, K., Dempfle, A., Franke, A., Schreiber, S., Laudes, M. „Role of wnt5a in metabolic inflammation in humans“ (2018), **J Clin Endocrinol Metab**, 103(11):4253-4264
  8. Kreutzer C, Peters S, Schulte DM, Fangmann D, Türk K, Wolf S, van Eimeren T, Ahrens M, Beckmann J, Schafmeyer C, Kerby T, Rohr A, Riedel C, Heinsen FA, Degenhardt F, Franke A, Rosenstiel P, Henning C, Freitag-Wolf S, Dempfle A, Jansen O, Schreiber S, Laudes M (2017). Hypothalamic inflammation in human obesity is mediated by environmental and genetic factors. **Diabetes**. 66(9):2407-2415.
  9. Wang J, Thingholm LB, Skiecevičienė J, Rausch P, Kummel M, Hov JR, Degenhardt F, Heinsen FA, Rühlemann MC, Szymczak S, Holm K, Esko T, Sun J, Pricop-Jeckstadt M, Al-Dury S, Bohov P, Bethune J, Sommer F, Ellinghaus D, Berge RK, Hübenthal M, Koch M, Schwarz K, Rimbach G, Hübbe P, Pan WH, Sheibani-Tezerji R, Häsler R, Rosenstiel P, D'Amato M, Cloppenborg-Schmidt K, Künzel S, Laudes M, Marschall HU, Lieb W, Nöthlings U, Karlsen TH, Baines JF, Franke A (2016). Genome-wide association analysis identifies variation in vitamin D receptor and other host factors influencing the gut microbiota. **Nat Genet**. 48(11):1396-1406.
  10. Müller N, Schulte DM, Türk K, Freitag-Wolf S, Hampe J, Zeuner R, Schröder JO, Gouni-Berthold I, Berthold HK, Krone W, Rose-John S, Schreiber S, Laudes M (2015). IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. **J Lipid Res**. 56(5):1034-42.

## Patents

1. Shellac microcapsule formulations and compositions for topical intestinal delivery of vitamin b3 (PCT/EP2017/058733).